Accelerating Rare Disease Diagnosis with Genomic Data
Genomenon CEO, Mike Klein, shares how Mastermind’s new Disease-Specific Curated Content is helping clinicians discover new treatment options for rare diseases.
Using Technology to Power Pharma and Clinical Genomics with Mike Klein
Genomenon CEO, Mike Klein met with Mike Maddox, host of ASK, to talk about Genomenon’s use of innovative technology to connect medical professionals with the scientific evidence they need to treat rare diseases and cancers.
Genomenon is 2020 Company of the Year in Global Clinical Genomics Interpretation
Genomenon was named the 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan today. The distinguished award highlights the superiority of Mastermind as a pioneering and first-in-class genomic database and leading research tool accelerating precision medicine. Below is the report in its entirety.